292 related articles for article (PubMed ID: 33180355)
1. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
Bowman S; Gass J; Weeks P
Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
[TBL] [Abstract][Full Text] [Related]
3. Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series.
Gernhofer YK; Banks DA; Golts E; Pretorius V
Semin Thorac Cardiovasc Surg; 2020 Winter; 32(4):763-769. PubMed ID: 31610233
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
[TBL] [Abstract][Full Text] [Related]
5. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support.
Pluenneke JC; Mohamed AM; Hayes CH; Berry TP; Thomas EL; Zhurav L; Kozinn JB; Haines MM; Welge JA
J Cardiothorac Vasc Anesth; 2023 Dec; 37(12):2511-2516. PubMed ID: 37775345
[TBL] [Abstract][Full Text] [Related]
7. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
8. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH; Phan YL; Spinler SA
Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
[TBL] [Abstract][Full Text] [Related]
9. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Vaduganathan M; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
Circ Cardiovasc Interv; 2016 Jun; 9(6):e003612. PubMed ID: 27313282
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
11. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
Tamborini Permunian E; Riva N; Guasti L; Squizzato A
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
Aguilar-Salinas P; Agnoletto GJ; Brasiliense LBC; Santos R; Granja MF; Gonsales D; Aghaebrahim A; Sauvageau E; Hanel RA
J Neurointerv Surg; 2019 Apr; 11(4):347-351. PubMed ID: 30552167
[TBL] [Abstract][Full Text] [Related]
13. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Groves EM; Bhatt DL; Steg PG; Deliargyris EN; Stone GW; Gibson CM; Hamm CW; Mahaffey KW; White HD; Angiolillo DJ; Prats J; Harrington RA; Price MJ
Circ Cardiovasc Interv; 2018 Apr; 11(4):e005635. PubMed ID: 29632238
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
Firstenberg MS; Dyke CM; Angiolillo DJ; Ramaiahm C; Price M; Brtko M; Welsby I; Chandna H; Holmes DR; Voeltz M; Tummala P; Hutyra M; Manoukian SV; Prats J; Todd M; Liu T; Chronos N; Dietrich M; Montalescot G; Cannon LA; Topo EJ
Heart Surg Forum; 2013 Apr; 16(2):E60-9. PubMed ID: 23625478
[TBL] [Abstract][Full Text] [Related]
15. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.
Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL;
J Am Coll Cardiol; 2017 Jan; 69(2):176-185. PubMed ID: 28081827
[TBL] [Abstract][Full Text] [Related]
16. What is the Role of Cangrelor in Patients Undergoing PCI?
Droppa M; Geisler T
Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
[TBL] [Abstract][Full Text] [Related]
17. Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study.
Johnson BV; Horton ER; Domenico C; Nathan AS; Fanaroff AC; Acker MA; Kolansky DM
J Invasive Cardiol; 2021 Dec; 33(12):E998-E1003. PubMed ID: 34817395
[TBL] [Abstract][Full Text] [Related]
18. Bleeding and thrombotic events occur early in children on durable ventricular assist devices.
Huang JY; Ignjatovic V; Sheridan BJ; Mathew J; D'Udekem Y; Brink J; Barton R; Callea G; Morsman D; Donath S; Opat S; Monagle P
Thromb Res; 2019 Jan; 173():65-70. PubMed ID: 30476715
[TBL] [Abstract][Full Text] [Related]
19. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
[TBL] [Abstract][Full Text] [Related]
20. Cangrelor PK/PD analysis in post-operative neonatal cardiac patients at risk for thrombosis.
Vargas D; Zhou H; Yu X; Diamond S; Yeh J; Allada V; Krishnamurthy G; Price M; Allen B; Alexander J; Schmidhofer J; Kreutzer J; Vincent J; Morell V; Bacha E; Diacovo T
J Thromb Haemost; 2021 Jan; 19(1):202-211. PubMed ID: 33078501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
